Researchers at the University of California, Davis and the Lawrence Livermore National Laboratory have developed a multiplexed immunoassay to measure a panel of five related molecular markers to achieve more relevant and reliable information for diagnosis of breast cancer
The presence and advancement of tumors has been shown to be associated with the expression of certain molecular markers. However, currently no single ideal marker exists for breast cancer.
Researchers at the University of California, Davis and the Lawrence Livermore National Laboratory (LLNL) have developed a multiplexed immunoassay to measure a panel of five related molecular markers to achieve more relevant and reliable information for diagnosis of breast cancer. Compared to current breast cancer detection methods, which are associated with long wait times, high costs, skilled labor, physical and psychological trauma and low accuracy, UC Davis and LLNL researchers have developed a rapid, cost effective, disposable, sensitive microarray based device capable of detecting the multiplexed panel of markers. In addition, UC Davis and LLNL researchers are also modeling the interaction of antigen and antibody in this type of an immunoassay and the effect of flow on the reaction rates in this device.
Country | Type | Number | Dated | Case |
United States Of America | Issued Patent | 9,366,668 | 06/14/2016 | 2005-529 |
multiplexed immunoassay, breast cancer, molecular markers, tumors, antigen antibody interaction, point of care, cancer biomarkers, multiplexed cancer detection